In contrast to the high rate of ESR1 mutation in advanced breast cancer (3,4,6,11), the prevalence of resistance mutations in primary breast tumors has been reportedly very low, ranging from 0% to 7% in published studies (3,4,12-14). Here, ESR1 is linked to breast cancer.